
  
    
      
        Background
        The mammalian <ENAMEX TYPE="ANIMAL">tachykinin</ENAMEX> peptides include neurokinin A
        (<ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX>), neurokinin B (NKB) and substance P (<ENAMEX TYPE="PRODUCT">SP</ENAMEX>) [ <ENAMEX TYPE="LAW">1</ENAMEX> ] . It
        is known that these <NUMEX TYPE="CARDINAL">three</NUMEX> <ENAMEX TYPE="PER_DESC">neuropeptides</ENAMEX> have a common
        C-terminal amino <ENAMEX TYPE="SUBSTANCE">acid sequence</ENAMEX> and that <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX> and <ENAMEX TYPE="PRODUCT">SP</ENAMEX> are
        derived from the preprotachykinin A gene, whereas <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX> is
        derived from the preprotachykinin B gene. It is also known
        that the biological actions of <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX> and <ENAMEX TYPE="PRODUCT">SP</ENAMEX> are mediated
        by <NUMEX TYPE="CARDINAL">three</NUMEX> <ENAMEX TYPE="SUBSTANCE">receptors</ENAMEX>, named <ENAMEX TYPE="PER_DESC">neurokinin</ENAMEX> (NK)-<NUMEX TYPE="CARDINAL">1</NUMEX>, <ENAMEX TYPE="SUBSTANCE">NK-2</ENAMEX> and NK-3
        [ <ENAMEX TYPE="LAW">2</ENAMEX> ] . Thus, the tachykinins have been implicated in
        several physiological actions such as salivation, the
        regulation of smooth muscle contraction, depolarization of
        central <ENAMEX TYPE="ORG_DESC">neurons</ENAMEX>, hyperactivity, interaction with
        <ENAMEX TYPE="ORGANIZATION">dopaminergic</ENAMEX> <ENAMEX TYPE="PRODUCT">A-10</ENAMEX> neurons mediating behavioral activation,
        regulation of blood pressure, and the transmission of the
        baroreceptor reflex [ <NUMEX TYPE="CARDINAL">3 4 5 6 7</NUMEX> ] . In addition, a loss of
        tachykinin-containing neurons has been described in
        neurodegenerative <ENAMEX TYPE="DISEASE">diseases</ENAMEX> [ <ENAMEX TYPE="LAW">8</ENAMEX> ] , suggesting that the
        decrease in the amount of tachykinins could be involved in
        these and other <ENAMEX TYPE="DISEASE">diseases</ENAMEX> [ <ENAMEX TYPE="LAW">9 10</ENAMEX> ] .
        Several inmunocytochemical, " in situ " hybridization
        and radioimmunoassay studies have demonstrated the
        distribution of tachykinins in the <ENAMEX TYPE="ANIMAL">rat</ENAMEX>, the <ENAMEX TYPE="ANIMAL">cat</ENAMEX> and the
        <ENAMEX TYPE="PRODUCT">monkey CNS</ENAMEX> [ <NUMEX TYPE="CARDINAL">11 12 13 14 15 16 17 18 19 20</NUMEX> ] . In the human
        brainstem, the presence of <ENAMEX TYPE="PRODUCT">SP</ENAMEX> has been widely studied [ <NUMEX TYPE="CARDINAL">21</NUMEX>
        <NUMEX TYPE="CARDINAL">22 23 24 25 26 27</NUMEX> ] . Moreover, in <ENAMEX TYPE="PER_DESC">humans</ENAMEX>, the neurokinin B
        <ENAMEX TYPE="ORGANIZATION">system</ENAMEX> has been studied in the cerebral cortex, hippocampus
        and the hypothalamus [ <TIMEX TYPE="DATE">28</TIMEX> ] . However, no data are
        available in the literature concerning the distribution of
        neurokinin-immunoreactive <ENAMEX TYPE="FAC_DESC">structures</ENAMEX> in the human
        <ENAMEX TYPE="ORGANIZATION">brainstem</ENAMEX>. Thus, in the present work we attempted to study
        in detail the distribution of <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> and cell bodies
        containing neurokinin in the human <ENAMEX TYPE="SUBSTANCE">brainstem</ENAMEX>, using an
        <ENAMEX TYPE="PERSON">immunoperoxidase</ENAMEX> technique, and to compare our findings
        with the distribution of other tachykinins previously
        described in the human <ENAMEX TYPE="SUBSTANCE">brainstem</ENAMEX> [ <NUMEX TYPE="CARDINAL">23 24 25 27</NUMEX> ] . Finally,
        we report here a widespread distribution of <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> and cell
        bodies containing <ENAMEX TYPE="SUBSTANCE">neurokinin</ENAMEX> in the human <ENAMEX TYPE="SUBSTANCE">brainstem</ENAMEX>.
      
      
        Results
        
          Distribution of NK-ir <ENAMEX TYPE="FAC_DESC">structures</ENAMEX> in the human
          medulla oblongata
          
            NK-ir cell bodies
            A low density of immunoreactive cell bodies
            containing <ENAMEX TYPE="SUBSTANCE">NK</ENAMEX> was observed caudally in the medullary
            central gray (<ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">1A; 4A</ENAMEX>), whereas more rostrally
            (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B) such clusters of NK-ir perikarya showed a
            moderate density. At the latter level (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B), a
            moderate density was also observed in the dorsal motor
            nucleus of the vagus and a low density below the
            nucleus of the solitary tract. More rostrally (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1C)
            <NUMEX TYPE="CARDINAL">three</NUMEX> <ENAMEX TYPE="PER_DESC">populations</ENAMEX> of immunoreactive cell <ENAMEX TYPE="PER_DESC">bodies</ENAMEX> were
            observed: the <NUMEX TYPE="ORDINAL">first</NUMEX> located along the midline (high
            <ENAMEX TYPE="ORGANIZATION">density</ENAMEX>); the <NUMEX TYPE="ORDINAL">second</NUMEX> in the dorsal motor nucleus of the
            <ENAMEX TYPE="ORGANIZATION">vagus</ENAMEX> (high density)(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 5A,5<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>); and the <NUMEX TYPE="ORDINAL">third</NUMEX> in the
            <ENAMEX TYPE="SUBSTANCE">reticular</ENAMEX> formation (nucleus reticularis
            gigantocellularis included)(moderate density), above
            the dorsal accessory olivary nucleus and the central
            <ENAMEX TYPE="ORGANIZATION">tegmental</ENAMEX> tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 6A,6<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>). In addition, a moderate
            density of immunoreactive cell bodies containing <ENAMEX TYPE="SUBSTANCE">NK</ENAMEX> was
            observed in the raphe obscurus (not shown in
            Figures).
          
          
            NK-ir fibers
            A high density of <ENAMEX TYPE="SUBSTANCE">immunoreactive fibers</ENAMEX> containing
            <ENAMEX TYPE="ORGANIZATION">NK</ENAMEX> was observed in the following <ENAMEX TYPE="GPE_DESC">regions</ENAMEX>: in the
            caudaldorsal part of the cuneate nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A), the
            <ENAMEX TYPE="PRODUCT">medullary</ENAMEX> central gray (<ENAMEX TYPE="PRODUCT">Figs.</ENAMEX> 1A<NUMEX TYPE="CARDINAL">,1</NUMEX><ENAMEX TYPE="PRODUCT">B; 4A</ENAMEX>), the dorsal
            motor nucleus of the vagus (<ENAMEX TYPE="PRODUCT">Figs.</ENAMEX> 1A,1B; 5A,5<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), the
            nucleus of the solitary tract (<ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">1B,1C; 5A</ENAMEX>), the
            raphe obscurus, the spinal trigeminal nucleus
            (gelatinosa part) (<ENAMEX TYPE="PRODUCT">Figs.</ENAMEX> 1A<NUMEX TYPE="CARDINAL">,1</NUMEX><ENAMEX TYPE="PRODUCT">B,1C; 7B</ENAMEX>), the inferior
            salivatory nucleus, the anterolateral system (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            1A<NUMEX TYPE="CARDINAL">,1</NUMEX><ENAMEX TYPE="PRODUCT">B,1C</ENAMEX>), the nucleus of the accessory nerve (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            1A), the <ENAMEX TYPE="DISEASE">lateral</ENAMEX> part of the <ENAMEX TYPE="SUBSTANCE">reticular</ENAMEX> formation (Figs.
            1B<NUMEX TYPE="CARDINAL">,1</NUMEX><ENAMEX TYPE="PRODUCT">C; 7A</ENAMEX>), the nucleus ambiguus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B,1C), the
            <ENAMEX TYPE="DISEASE">lateral reticular nucleus</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B,1C), and the dorsal
            accessory olivary nucleus (<ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">1C; 6B</ENAMEX>). A moderate
            <ENAMEX TYPE="PERSON">density</ENAMEX> was found in the gracile nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A,1<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>),
            the caudal-ventral part of the cuneate nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            1A), as well as in the whole nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B), the
            caudal end of the motor hypoglossal nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A),
            the rubrospinal tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A<NUMEX TYPE="CARDINAL">,1</NUMEX><ENAMEX TYPE="PRODUCT">B,1C</ENAMEX>), the medial C 
            <NUMEX TYPE="CARDINAL">1</NUMEX> cells (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A), the spinal
            <ENAMEX TYPE="ORGANIZATION">trigeminal</ENAMEX> tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B,1C), the medial part of the
            <ENAMEX TYPE="SUBSTANCE">reticular</ENAMEX> formation (nucleus reticularis
            gigantocellularis included) (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B,1C), the motor
            hypoglossal nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B,1C), the medial accessory
            olivary nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B), the medial vestibular
            <ENAMEX TYPE="PERSON">nucleus</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1C) and in the spinal (inferior)
            vestibular nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1C).
            A low density of <ENAMEX TYPE="SUBSTANCE">immunoreactive fibers</ENAMEX> containing NK
            was found in the fasciculus gracilis (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A), the
            fasciculus cuneatus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A,1<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), the spinal trigeminal
            <ENAMEX TYPE="PERSON">tract</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A), the reticulospinal tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            1A<NUMEX TYPE="CARDINAL">,1</NUMEX><ENAMEX TYPE="PRODUCT">B,1C</ENAMEX>), the dorsal spinocerebellar tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A),
            the vestibulospinal tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A,1<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), the spinal
            trigeminal nucleus (magnocellular part) (<ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">1A; 7B</ENAMEX>),
            the pyramidal tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A<NUMEX TYPE="CARDINAL">,1</NUMEX><ENAMEX TYPE="PRODUCT">B,1C</ENAMEX>), the <ENAMEX TYPE="DISEASE">lateral</ENAMEX>
            cuneate nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B,1C), the restiform body (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            1B,1C), the medial lemniscus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B,1C), the
            principal part of the inferior olivary nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            1B,1C), and in the midline (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1C), whereas single
            immunoreactive <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> were observed in the ventral
            <ENAMEX TYPE="ORGANIZATION">spinocerebellar</ENAMEX> tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A<NUMEX TYPE="CARDINAL">,1</NUMEX><ENAMEX TYPE="PRODUCT">B,1C</ENAMEX>), the medial
            longitudinal fascicle (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1A<NUMEX TYPE="CARDINAL">,1</NUMEX><ENAMEX TYPE="PRODUCT">B,1C</ENAMEX>), the
            glossopharyngeal nerve, the tectospinal tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            1A<NUMEX TYPE="CARDINAL">,1</NUMEX><ENAMEX TYPE="PRODUCT">B,1C</ENAMEX>), the central <ENAMEX TYPE="ORG_DESC">tegmental</ENAMEX> tract(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1B,1C), the
            dorsal part of the medial longitudinal fascicle(<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            1B,1C), the medial accessory olivary nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 1C),
            the solitary tract (<ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">1C; 5A</ENAMEX>), and in the
            glossopharyngeal <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> that join the spinal trigeminal
            tract.
          
        
        
          Distribution of NK-ir <ENAMEX TYPE="FAC_DESC">structures</ENAMEX> in the human
          <ENAMEX TYPE="CONTACT_INFO">pons</ENAMEX>
          
            NK-ir cell bodies
            We observed a moderate density of immunoreactive
            cell bodies in the caudal (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A) and in the rostral
            (close to the central <ENAMEX TYPE="ORG_DESC">tegmental</ENAMEX> tract)(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2C)
            <ENAMEX TYPE="SUBSTANCE">reticular</ENAMEX> formation, between the superior cerebellar
            <ENAMEX TYPE="ORGANIZATION">peduncle</ENAMEX> and the anterolateral system, as well as in
            the tegmental central gray (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2C). In the nucleus
            prepositus hypoglossi (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), a low density of
            immunoreactive cell <ENAMEX TYPE="PER_DESC">bodies</ENAMEX> was found.
          
          
            NK-ir fibers
            In the <ENAMEX TYPE="DISEASE">lateral</ENAMEX> part (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A,2<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>) and in the
            medial-most area (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2C) of the <ENAMEX TYPE="SUBSTANCE">reticular</ENAMEX> formation,
            the nucleus of the solitary tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the
            superior salivatory nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), and in the
            <ENAMEX TYPE="PRODUCT">tegmental</ENAMEX> central gray (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2B,2C) a high density of
            <ENAMEX TYPE="SUBSTANCE">NK-ir fibers</ENAMEX> was visualized. A moderate density was
            observed in the following <ENAMEX TYPE="GPE_DESC">regions</ENAMEX>: the rubrospinal
            <ENAMEX TYPE="PERSON">tract</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A,2<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), the anterolateral system (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            2A<NUMEX TYPE="CARDINAL">,2</NUMEX><ENAMEX TYPE="PRODUCT">B,2C</ENAMEX>), the medial part of the <ENAMEX TYPE="SUBSTANCE">reticular</ENAMEX> formation
            (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A,2<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), the medial parabrachial nucleus (close to
            the superior cerebellar peduncle)(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2B), the spinal
            trigeminal nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the superior vestibular
            <ENAMEX TYPE="PERSON">nucleus</ENAMEX>, the nucleus prepositus hypoglossi (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A),
            and the nuclei of the <ENAMEX TYPE="DISEASE">lateral lemniscus</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2B,2C),
            whereas a low density of immunoreactive fibers
            containing <ENAMEX TYPE="SUBSTANCE">NK</ENAMEX> was found in the spinal trigeminal
            <ENAMEX TYPE="PERSON">tract</ENAMEX>(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the restiform body (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the
            medial lemniscus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A<NUMEX TYPE="CARDINAL">,2</NUMEX><ENAMEX TYPE="PRODUCT">B,2C</ENAMEX>), the central tegmental
            <ENAMEX TYPE="PERSON">tract</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A<NUMEX TYPE="CARDINAL">,2</NUMEX><ENAMEX TYPE="PRODUCT">B,2C</ENAMEX>), the <ENAMEX TYPE="DISEASE">lateral</ENAMEX> and medial
            vestibular nuclei (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the motor facial nucleus
            (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the superior olive (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A,2<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), the
            corticospinal <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A<NUMEX TYPE="CARDINAL">,2</NUMEX><ENAMEX TYPE="PRODUCT">B,2C</ENAMEX>), the pontine
            <ENAMEX TYPE="ORGANIZATION">nuclei</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A<NUMEX TYPE="CARDINAL">,2</NUMEX><ENAMEX TYPE="PRODUCT">B,2C</ENAMEX>), the abducens nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A),
            the <ENAMEX TYPE="PER_DESC">principal</ENAMEX> trigeminal nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2B), the caudal
            end of the chief sensory nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2B), the
            superior cerebellar peduncle (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A<NUMEX TYPE="CARDINAL">,2</NUMEX><ENAMEX TYPE="PRODUCT">B,2C</ENAMEX>) and in the
            middle cerebellar peduncle (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2C), <ENAMEX TYPE="PERSON">Finally</ENAMEX>, single
            immunoreactive <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> were visualized in the ventral
            <ENAMEX TYPE="ORGANIZATION">spinocerebellar</ENAMEX> tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A,2<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), the medial
            longitudinal fascicle (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A<NUMEX TYPE="CARDINAL">,2</NUMEX><ENAMEX TYPE="PRODUCT">B,2C</ENAMEX>), the tectospinal
            <ENAMEX TYPE="PERSON">tract</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A<NUMEX TYPE="CARDINAL">,2</NUMEX><ENAMEX TYPE="PRODUCT">B,2C</ENAMEX>), the dorsal part of the medial
            longitudinal fascicle (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A,2<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), the solitary
            <ENAMEX TYPE="PERSON">tract</ENAMEX>(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the internal genu of the facial nerve
            (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the facial nerve (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the trapezoid
            body (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the trapezoid nucleus(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), the
            pontocerebellar <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A<NUMEX TYPE="CARDINAL">,2</NUMEX><ENAMEX TYPE="PRODUCT">B,2C</ENAMEX>), the ventral
            <ENAMEX TYPE="ORGANIZATION">trigeminothalamic</ENAMEX> tract(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A<NUMEX TYPE="CARDINAL">,2</NUMEX><ENAMEX TYPE="PRODUCT">B,2C</ENAMEX>), the
            juxtarestiform <ENAMEX TYPE="ORG_DESC">body</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2A), and the trigeminal nerve
            (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2C).
          
        
        
          Distribution of NK-ir <ENAMEX TYPE="FAC_DESC">structures</ENAMEX> in the human
          mesencephalon
          
            NK-ir cell bodies
            In the mesencephalon <NUMEX TYPE="CARDINAL">two</NUMEX> <ENAMEX TYPE="PER_DESC">populations</ENAMEX> of cell bodies
            containing <ENAMEX TYPE="SUBSTANCE">NK</ENAMEX> were observed. The <NUMEX TYPE="ORDINAL">first</NUMEX> (high density)
            was located above the periaqueductal gray and the
            central nucleus of the inferior colliculus and extended
            into the latter nucleus (<ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">3A</ENAMEX>; 8A,8B; 9A,9<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>). The
            <NUMEX TYPE="ORDINAL">second</NUMEX> was observed in the periaqueductal gray (high
            <ENAMEX TYPE="ORGANIZATION">density</ENAMEX>) (<ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">3B; 10A</ENAMEX>) and in the <ENAMEX TYPE="SUBSTANCE">reticular</ENAMEX> formation
            (low density) (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3B). In the caudal and rostral
            regions of the periaqueductal gray a low density of
            NK-ir perikarya was found in the ventromedial part of
            the nucleus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A,3C).
          
          
            NK-ir fibers
            A high density of <ENAMEX TYPE="SUBSTANCE">NK-ir fibers</ENAMEX> was found above the
            periaqueductal gray and the central nucleus of the
            inferior colliculus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A), the <ENAMEX TYPE="SUBSTANCE">reticular</ENAMEX> formation
            (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A<NUMEX TYPE="CARDINAL">,3</NUMEX><ENAMEX TYPE="PRODUCT">B,3C</ENAMEX>), the periaqueductal gray (Figs.
            3A<NUMEX TYPE="CARDINAL">,3</NUMEX><ENAMEX TYPE="PRODUCT">B,3C; 10A</ENAMEX>), the <ENAMEX TYPE="GPE_DESC">lateral zone</ENAMEX> of the inferior
            <ENAMEX TYPE="ORGANIZATION">colliculus</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A), the <ENAMEX TYPE="DISEASE">lateral lemniscus</ENAMEX>(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A),
            the dorsal trigeminothalamic tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A<NUMEX TYPE="CARDINAL">,3</NUMEX><ENAMEX TYPE="PRODUCT">B,3C</ENAMEX>), the
            superior colliculus (<ENAMEX TYPE="CONTACT_INFO">layers 2-6</ENAMEX>)(<ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">3B,3C; 10B</ENAMEX>), the
            substantia nigra(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3B,3C), and in the pallidonigral,
            <ENAMEX TYPE="ORGANIZATION">nigrostriatal</ENAMEX> and corticonigral <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3B,3C); a
            moderate density in the spinotectal tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            3A<NUMEX TYPE="CARDINAL">,3</NUMEX><ENAMEX TYPE="PRODUCT">B,3C</ENAMEX>), the spinothalamic tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A<NUMEX TYPE="CARDINAL">,3</NUMEX><ENAMEX TYPE="PRODUCT">B,3C</ENAMEX>), the
            ventral trigeminothalamic tract(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A<NUMEX TYPE="CARDINAL">,3</NUMEX><ENAMEX TYPE="PRODUCT">B,3C</ENAMEX>), the
            superior cerebellar peduncle (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A), the dorsal part
            of the pontine nuclei (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3B), the interpeduncular
            <ENAMEX TYPE="PERSON">nucleus</ENAMEX>(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3B,3C), and the rubrospinal tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            3C).
            In the central nucleus of the inferior colliculus
            (<ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">3A</ENAMEX>; <TIMEX TYPE="DATE">8B</TIMEX>; 9A,9<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), the medial lemniscus (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            3A<NUMEX TYPE="CARDINAL">,3</NUMEX><ENAMEX TYPE="PRODUCT">B,3C</ENAMEX>), the central <ENAMEX TYPE="ORG_DESC">tegmental</ENAMEX> tract (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A<NUMEX TYPE="CARDINAL">,3</NUMEX><ENAMEX TYPE="PRODUCT">B,3C</ENAMEX>),
            the corticospinal <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A), the pontine nuclei
            (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A), the crus cerebri(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A<NUMEX TYPE="CARDINAL">,3</NUMEX><ENAMEX TYPE="PRODUCT">B,3C</ENAMEX>), the red
            <ENAMEX TYPE="PERSON">nucleus</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3C), the <ENAMEX TYPE="PER_DESC">superior colliculus</ENAMEX> (layer
            <ENAMEX TYPE="ORGANIZATION">l</ENAMEX>)(<ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">3B; 10B</ENAMEX>), the superior cerebellar peduncle
            (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3C) a low density of <ENAMEX TYPE="SUBSTANCE">NK-ir fibers</ENAMEX> was found,
            whereas single <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> were observed in the medial
            longitudinal fascicle (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A<NUMEX TYPE="CARDINAL">,3</NUMEX><ENAMEX TYPE="PRODUCT">B,3C</ENAMEX>), the tectospinal
            <ENAMEX TYPE="PERSON">tract</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3A,3<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), the pontocerebellar <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
            3A), the trochlear nerve (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3B), the oculomotor
            <ENAMEX TYPE="PERSON">nucleus</ENAMEX>(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3C), the dorsal and ventral tegmental
            <ENAMEX TYPE="ORGANIZATION">decussations</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3C), and in the oculomotor
            <ENAMEX TYPE="PERSON">nerve</ENAMEX>(<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3C).
          
        
      
      
        Discussion
        
          Distribution of <ENAMEX TYPE="ORGANIZATION">NK</ENAMEX> in the mammalian
          brainstem
          In a previous study, we described the distribution of
          NK-ir <ENAMEX TYPE="FAC_DESC">structures</ENAMEX> in the <ENAMEX TYPE="ANIMAL">cat brainstem</ENAMEX> [ <TIMEX TYPE="DATE">15</TIMEX> ] . Although
          the presence of <ENAMEX TYPE="SUBSTANCE">NK-ir fibers</ENAMEX> is widely distributed in
          both <ENAMEX TYPE="ANIMAL">cat</ENAMEX> and human <ENAMEX TYPE="SUBSTANCE">brainstems</ENAMEX>, it seems that the
          distribution is a little more widespread in <ENAMEX TYPE="PER_DESC">humans</ENAMEX> than
          in <ENAMEX TYPE="ANIMAL">cats</ENAMEX>. Thus, for example, in the former, we found NK-ir
          <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> in the <ENAMEX TYPE="PER_DESC">superior colliculus</ENAMEX>, the restiform <ENAMEX TYPE="ORG_DESC">body</ENAMEX>,
          the pyramidal tract, and in the pontine nuclei, in which
          in the <ENAMEX TYPE="ANIMAL">cat</ENAMEX> no immunoreactive <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> were found [ <TIMEX TYPE="DATE">15</TIMEX> ] .
          Comparing the distribution of cell bodies containing NK
          in both <ENAMEX TYPE="ANIMAL">cat</ENAMEX> and human <ENAMEX TYPE="SUBSTANCE">brainstems</ENAMEX>, it seems that the
          distribution is widespread in the feline (see [ <TIMEX TYPE="DATE">15</TIMEX> ] ).
          In both <ENAMEX TYPE="ANIMAL">species</ENAMEX> NK-ir perikarya were found in the
          periaqueductal gray and in the inferior colliculus.
          However, in the <ENAMEX TYPE="ANIMAL">cat</ENAMEX> cell bodies containing <ENAMEX TYPE="SUBSTANCE">NK</ENAMEX> were
          observed in the <ENAMEX TYPE="PER_DESC">superior colliculus</ENAMEX>, the interpeduncular
          <ENAMEX TYPE="PERSON">nucleus</ENAMEX>, the <ENAMEX TYPE="DISEASE">lateral reticular nucleus</ENAMEX>, and in the
          nucleus of the solitary tract, as well as in other
          brainstem localizations, in which we did not observe
          NK-ir cell bodies in the same brainstem regions of
          <ENAMEX TYPE="PER_DESC">humans</ENAMEX>. By contrast, in <ENAMEX TYPE="PER_DESC">humans</ENAMEX>, we found NK-ir perikarya
          located in the dorsal motor nucleus of the vagus, in
          which in the <ENAMEX TYPE="ANIMAL">cat</ENAMEX> no immunoreactive cell <ENAMEX TYPE="PER_DESC">bodies</ENAMEX> were found
          [ <TIMEX TYPE="DATE">15</TIMEX> ] . The differences observed in both species
          concerning the distribution of cell bodies containing NK
          could be due to technical considerations, since in the
          <ENAMEX TYPE="ANIMAL">cat colchicine</ENAMEX> was administered in the <NUMEX TYPE="ORDINAL">fourth</NUMEX> ventricle
          in order to accumulate the peptide in cell bodies [ <TIMEX TYPE="DATE">15</TIMEX> ]
          .
          Our data are in agreement with previous results
          described in the <ENAMEX TYPE="ANIMAL">rat brainstem</ENAMEX>, using radioimmunoassay
          techniques [ <NUMEX TYPE="CARDINAL">29 30</NUMEX> ] . Thus, these <ENAMEX TYPE="PER_DESC">latter authors</ENAMEX> found
          higher levels of <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX> and lower levels of <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX> in both the
          <ENAMEX TYPE="ORGANIZATION">midbrain</ENAMEX> and the medulla oblongata of the <ENAMEX TYPE="ANIMAL">rat</ENAMEX> [ <TIMEX TYPE="DATE">30</TIMEX> ] . In
          both regions of the human <ENAMEX TYPE="SUBSTANCE">brainstem</ENAMEX>, we observed a high
          density of NK-ir structures. Moreover, in the midbrain of
          the rat those <ENAMEX TYPE="PER_DESC">authors</ENAMEX> described <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX> in the substantia
          nigra, the interpeduncular nucleus and the periaqueductal
          <ENAMEX TYPE="PERSON">gray</ENAMEX> [ <TIMEX TYPE="DATE">29</TIMEX> ] , just as we found NK-ir <ENAMEX TYPE="FAC_DESC">structures</ENAMEX> in these
          nuclei of the human brainstem when using
          immunocytochemical techniques.
          Several studies have shown the distribution of NKA
          (<ENAMEX TYPE="DISEASE">preprotachykinin A mRNA</ENAMEX>) [ <TIMEX TYPE="DATE">12</TIMEX> ] and <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX> (peptide-<NUMEX TYPE="CARDINAL">2</NUMEX>;
          <ENAMEX TYPE="ORGANIZATION">preprotachykinin</ENAMEX> B mRNA) [ <NUMEX TYPE="CARDINAL">14 16 17 20</NUMEX> ] in the <ENAMEX TYPE="ORGANIZATION">CNS</ENAMEX> of
          the <ENAMEX TYPE="ANIMAL">rat</ENAMEX>. The work of <ENAMEX TYPE="ORGANIZATION">Harlan et al.</ENAMEX> [ <TIMEX TYPE="DATE">12</TIMEX> ] revealed a more
          widespread distribution of neurons encoding <ENAMEX TYPE="PRODUCT">SP</ENAMEX> and NKA
          preprotachykinin mRNA in the <ENAMEX TYPE="ANIMAL">rat brainstem</ENAMEX> than the
          distribution of NK-ir cell bodies observed in the human
          <ENAMEX TYPE="ORGANIZATION">brainstem</ENAMEX>. In addition, taking together the results of
          the other <NUMEX TYPE="CARDINAL">four</NUMEX> works [ <NUMEX TYPE="CARDINAL">14 16 17 20</NUMEX> ] , it also seems that
          neurons expressing NKB are more widely distributed in the
          <ENAMEX TYPE="ANIMAL">rat brainstem</ENAMEX> than those observed containing <ENAMEX TYPE="SUBSTANCE">NK</ENAMEX> in the
          human brainstem. However, in the <ENAMEX TYPE="ANIMAL">rat</ENAMEX>, those <ENAMEX TYPE="PER_DESC">authors</ENAMEX> did
          not find either <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX> nor <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX> in the dorsal motor nucleus
          of the vagus and in the nucleus prepositus hypoglossi, in
          which, in <ENAMEX TYPE="PER_DESC">humans</ENAMEX>, we observed NK-ir structures. Future
          works must address the issue of whether the discrepancies
          observed in the distribution of neurokinin in both
          <ENAMEX TYPE="ANIMAL">species</ENAMEX> are due to technical and/or species
          differences.
        
        
          Distribution of tachykinins in the human
          brainstem
          In comparison with previous works in which the
          distribution of <ENAMEX TYPE="PRODUCT">SP</ENAMEX> was described in the human <ENAMEX TYPE="SUBSTANCE">brainstem</ENAMEX> [
          <NUMEX TYPE="CARDINAL">24 25 26 27</NUMEX> ] , it seems that in general, taking together
          the results obtained from the <NUMEX TYPE="CARDINAL">four</NUMEX> above-mentioned works,
          the distribution of NK-ir <ENAMEX TYPE="FAC_DESC">structures</ENAMEX> in this region of
          the human <ENAMEX TYPE="SUBSTANCE">CNS</ENAMEX> is quite similar. Thus, for example, <ENAMEX TYPE="PRODUCT">SP</ENAMEX> and
          NK-ir structures have been observed in the same human
          brainstem areas such as the periaqueductal gray,
          substantia nigra, parabrachial nucleus, inferior and
          superior colliculi, <ENAMEX TYPE="SUBSTANCE">reticular</ENAMEX> formation, nucleus of the
          solitary tract, red nucleus, interpeduncular nucleus,
          medial vestibular nucleus, cuneate nucleus, spinal
          trigeminal nucleus, and the dorsal motor nucleus of the
          <ENAMEX TYPE="ORGANIZATION">vagus</ENAMEX>. However, for example, we found NK-ir structures
          (the <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> used in this study principally recognizes
          <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX>)(see specificity of the antiserum in <ENAMEX TYPE="GPE">Methods</ENAMEX>) in the
          human brainstem in the <ENAMEX TYPE="DISEASE">lateral cuneate nucleus</ENAMEX> and in the
          <ENAMEX TYPE="ORGANIZATION">pyramidal</ENAMEX> tract, in which no <ENAMEX TYPE="PRODUCT">SP-</ENAMEX>ir structure has been
          described in <ENAMEX TYPE="PER_DESC">humans</ENAMEX> [ <NUMEX TYPE="CARDINAL">24 25 26 27</NUMEX> ] . It is known that
          both neuropeptides, <ENAMEX TYPE="PRODUCT">SP</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX>, are derived from the same
          precursor. Thus, the differences found in the
          distribution of both <ENAMEX TYPE="SUBSTANCE">neuroactive substances</ENAMEX> in the human
          <ENAMEX TYPE="ORGANIZATION">brainstem</ENAMEX> could be due to the intraneuronal segregation
          transport of the peptides and/or the different processing
          of the precursor [see [ <TIMEX TYPE="DATE">31</TIMEX> ] ]. Another possibility could
          be that the immunoreactivity observed in those nuclei of
          the human brainstem in which NK-ir structures, but not
          <ENAMEX TYPE="PRODUCT">SP</ENAMEX>, are found is due to <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX> (the <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> used here also
          <ENAMEX TYPE="ORGANIZATION">recognizes NKB</ENAMEX>). As is known, this latter tachykinin
          derives from the pre-protachykinin B gene, whereas <ENAMEX TYPE="PRODUCT">SP</ENAMEX> and
          <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX> derive from another precursor, the pre-protachykinin
          A gene. Finally, <ENAMEX TYPE="PRODUCT">SP-</ENAMEX>immunoreactive cell <ENAMEX TYPE="PER_DESC">bodies</ENAMEX> have been
          found in the human brainstem; for example, in the
          superior colliculus and in the spinal trigeminal nucleus
          [ <NUMEX TYPE="CARDINAL">22 32</NUMEX> ] , in which we did not find NK-ir perikarya.
        
        
          Possible physiological actions of the <ENAMEX TYPE="ORGANIZATION">NK</ENAMEX> in the
          human brainstem
          The widespread distribution of NK-ir <ENAMEX TYPE="FAC_DESC">structures</ENAMEX> in the
          human brainstem suggests that the peptide might be
          involved in several physiological actions, acting as a
          <ENAMEX TYPE="ORGANIZATION">neurotransmitter</ENAMEX> and/or neuromodulator. Thus, for
          example, the presence of <ENAMEX TYPE="ORGANIZATION">NK</ENAMEX> in the nucleus of the
          solitary tract, the dorsal motor nucleus of the vagus,
          the periaqueductal gray, the spinal trigeminal nucleus,
          the interpeduncular nucleus, the substantia nigra, the
          parabrachial nucleus, and the <ENAMEX TYPE="PER_DESC">superior</ENAMEX> and inferior
          <ENAMEX TYPE="ORGANIZATION">colliculi</ENAMEX> indicates that <ENAMEX TYPE="ORGANIZATION">NK</ENAMEX> could be involved in a broad
          range of physiological functions such as in
          <ENAMEX TYPE="ORGANIZATION">cardiovascular</ENAMEX>, anti-nociceptive, nociceptive, motor,
          <ENAMEX TYPE="ORGANIZATION">respiratory</ENAMEX>, visual and auditory mechanisms. Moreover, a
          possible interaction between <ENAMEX TYPE="ORGANIZATION">NK</ENAMEX> and other neuropeptides
          (e.g., neurotensin and <ENAMEX TYPE="SUBSTANCE">somatostatin</ENAMEX>) in the human
          <ENAMEX TYPE="ORGANIZATION">brainstem</ENAMEX> could be suggested, since in almost all the
          nuclei, located in the dorsal brainstem of <ENAMEX TYPE="PER_DESC">humans</ENAMEX>,
          immunoreactive <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> containing <ENAMEX TYPE="SUBSTANCE">NK</ENAMEX>, neurotensin and
          <ENAMEX TYPE="SUBSTANCE">somatostatin</ENAMEX> have been observed [ <NUMEX TYPE="CARDINAL">33 34</NUMEX> ] . This
          <ENAMEX TYPE="PERSON">observation</ENAMEX> is in agreement with the results found in the
          <ENAMEX TYPE="ANIMAL">cat brainstem</ENAMEX>, in which a clear anatomical relationship
          between the <NUMEX TYPE="CARDINAL">three</NUMEX> above-mentioned neuropeptides has been
          indicated [ <TIMEX TYPE="DATE">15</TIMEX> ] . Finally, we hope that our study will
          serve to compare the distribution of NK-ir structures
          found in normal human brainstems with those observed, in
          the future, in brainstems showing a given pathology
          (e.g., <ENAMEX TYPE="DISEASE">Parkinson</ENAMEX> or <ENAMEX TYPE="DISEASE">Alzheimer disease</ENAMEX>); since, for
          example, the loss of <ENAMEX TYPE="PRODUCT">SP-containing</ENAMEX> <ENAMEX TYPE="PRODUCT_DESC">neurons</ENAMEX> has been
          described in the brainstem of <ENAMEX TYPE="PER_DESC">people</ENAMEX> with <ENAMEX TYPE="DISEASE">Parkinson's</ENAMEX>
          disease [ <ENAMEX TYPE="LAW">8</ENAMEX> ] .
        
      
      
        Conclusions
        <NUMEX TYPE="CARDINAL">1</NUMEX>. There is a widespread distribution of immunoreactive
        structures containing <ENAMEX TYPE="SUBSTANCE">neurokinin</ENAMEX> in the human
        <ENAMEX TYPE="ORGANIZATION">brainstem</ENAMEX>.
        <NUMEX TYPE="CARDINAL">2</NUMEX>. The highest density of <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> and cell bodies
        containing <ENAMEX TYPE="SUBSTANCE">neurokinin</ENAMEX> was generally observed in the dorsal
        part of the human <ENAMEX TYPE="SUBSTANCE">brainstem</ENAMEX>.
        <NUMEX TYPE="CARDINAL">3</NUMEX>. The widespread distribution of
        neurokinin-immunoreactive <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> and cell <ENAMEX TYPE="PER_DESC">bodies</ENAMEX> indicates
        that neurokinin might be involved in several physiological
        functions, acting as a neurotransmitter and/or
        <ENAMEX TYPE="ORGANIZATION">neuromodulator</ENAMEX>.
      
      
        Methods
        
          Immunocytochemistry
          In order to avoid possible interference by endogenous
          peroxidase, free-floating sections were treated with
          distilled <ENAMEX TYPE="SUBSTANCE">water</ENAMEX> containing <ENAMEX TYPE="ORGANIZATION">NH</ENAMEX> 
          <NUMEX TYPE="CARDINAL">3</NUMEX> (<NUMEX TYPE="PERCENT">20%</NUMEX>), H 
          <NUMEX TYPE="CARDINAL">2</NUMEX> <ENAMEX TYPE="PERSON">O</ENAMEX> 
          <NUMEX TYPE="CARDINAL">2</NUMEX> (<NUMEX TYPE="PERCENT">30%</NUMEX>) and <ENAMEX TYPE="PERSON">NaOH</ENAMEX> (<NUMEX TYPE="PERCENT">1%</NUMEX>) for <TIMEX TYPE="DATE">20</TIMEX> min [ <NUMEX TYPE="CARDINAL">35</NUMEX>
          ] . Then, the <ENAMEX TYPE="FAC_DESC">sections</ENAMEX> were washed for <TIMEX TYPE="TIME">20 min</TIMEX> in <ENAMEX TYPE="ORGANIZATION">PBS</ENAMEX> and
          preincubated for <TIMEX TYPE="TIME">30 min</TIMEX> in <ENAMEX TYPE="ORGANIZATION">PBS</ENAMEX> containing <NUMEX TYPE="PERCENT">1%</NUMEX> normal horse
          <ENAMEX TYPE="ORGANIZATION">serum</ENAMEX> and <NUMEX TYPE="PERCENT">0.3%</NUMEX> <ENAMEX TYPE="ORGANIZATION">Triton X-100</ENAMEX>. The <ENAMEX TYPE="FAC_DESC">sections</ENAMEX> were then
          washed for <TIMEX TYPE="TIME">30 min in the last</TIMEX> <ENAMEX TYPE="SUBSTANCE">solution</ENAMEX> containing caseine
          (<NUMEX TYPE="PERCENT">0.5%</NUMEX>) and were incubated <TIMEX TYPE="TIME">overnight</TIMEX> at <NUMEX TYPE="ORDINAL">4°C</NUMEX> in <ENAMEX TYPE="ORGANIZATION">PBS</ENAMEX>
          <ENAMEX TYPE="LAW">containing Triton X-100</ENAMEX> (<NUMEX TYPE="PERCENT">0.3%</NUMEX>) and normal <ENAMEX TYPE="ANIMAL">horse</ENAMEX> serum
          (<NUMEX TYPE="PERCENT">1%</NUMEX>), as well as <ENAMEX TYPE="NATIONALITY">anti-neurokinin</ENAMEX> antiserum, and diluted
          <NUMEX TYPE="CARDINAL">1/15000</NUMEX> - <NUMEX TYPE="CARDINAL">1/30000</NUMEX>. The <ENAMEX TYPE="FAC_DESC">sections</ENAMEX> were then washed in <ENAMEX TYPE="ORGANIZATION">PBS</ENAMEX>
          (<TIMEX TYPE="TIME">30 min</TIMEX>) and incubated for <TIMEX TYPE="TIME">60 min</TIMEX> at room temperature
          with biotinylated antirabbit <ENAMEX TYPE="SUBSTANCE">immunogamma globulin</ENAMEX> diluted
          <NUMEX TYPE="CARDINAL">1/200</NUMEX> in <ENAMEX TYPE="ORGANIZATION">PBS</ENAMEX>. After a <NUMEX TYPE="CARDINAL">30</NUMEX> <ENAMEX TYPE="ORG_DESC">min wash</ENAMEX> with <ENAMEX TYPE="ORGANIZATION">PBS</ENAMEX>, the sections
          were incubated for <NUMEX TYPE="CARDINAL">1</NUMEX> h with avidin-<NUMEX TYPE="CARDINAL">biotin</NUMEX>-peroxidase
          complex (<ENAMEX TYPE="ORGANIZATION">Vectastain</ENAMEX>) (diluted <NUMEX TYPE="MONEY">1/100</NUMEX>). Finally, after
          washing the <ENAMEX TYPE="FAC_DESC">sections</ENAMEX> in <ENAMEX TYPE="ORGANIZATION">PBS</ENAMEX> (<TIMEX TYPE="TIME">30 min</TIMEX>) and <ENAMEX TYPE="ORGANIZATION">Tris-HCl</ENAMEX> buffer
          (<NUMEX TYPE="MONEY">pH 7.6</NUMEX>)(<TIMEX TYPE="TIME">10 min</TIMEX>), the tissue-bound peroxidase was
          developed by H 
          <NUMEX TYPE="CARDINAL">2</NUMEX> <ENAMEX TYPE="PERSON">O</ENAMEX> 
          <ENAMEX TYPE="PRODUCT">2</ENAMEX> using <ENAMEX TYPE="CONTACT_INFO">3, 3</ENAMEX>' diaminobenzidine as
          <ENAMEX TYPE="ORGANIZATION">chromogen</ENAMEX>. The <ENAMEX TYPE="FAC_DESC">sections</ENAMEX> were rinsed with <ENAMEX TYPE="ORGANIZATION">PBS</ENAMEX> and
          coverslipped with <ENAMEX TYPE="ORGANIZATION">PBS/Glycerol</ENAMEX> (<NUMEX TYPE="MONEY">1/1</NUMEX>).
        
        
          Specificity of the antiserum
          Polyclonal <ENAMEX TYPE="NATIONALITY">anti-neurokinin</ENAMEX> <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> was raised in
          <ENAMEX TYPE="ORGANIZATION">rabbits</ENAMEX> against <ENAMEX TYPE="SUBSTANCE">immunogens</ENAMEX> prepared by coupling the
          <ENAMEX TYPE="ORGANIZATION">synthetic NKA</ENAMEX> peptide (<ENAMEX TYPE="ORGANIZATION">Bachem</ENAMEX>, <ENAMEX TYPE="GPE">Switzerland</ENAMEX>) to a carrier
          <ENAMEX TYPE="SUBSTANCE">protein</ENAMEX> (human serum albumin) with glutaraldehyde. The
          specificity of the immunostaining was controlled by
          omission of the neurokinin <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> in the first
          incubation bath. No immunoreactivity was found. Moreover,
          <ENAMEX TYPE="ORGANIZATION">control</ENAMEX> sections were incubated in the primary antiserum
          previously absorbed by neurokinin A or neurokinin <ENAMEX TYPE="ORGANIZATION">B.</ENAMEX>
          Inhibition of staining was obtained after preincubation
          of the <NUMEX TYPE="ORDINAL">first</NUMEX> antiserum with <ENAMEX TYPE="DISEASE">neurokinin A</ENAMEX> (<NUMEX TYPE="CARDINAL">10</NUMEX> -4and 10
          <ENAMEX TYPE="CONTACT_INFO">-5M</ENAMEX>) or with neurokinin B (<NUMEX TYPE="CARDINAL">10</NUMEX> -3M). Moreover, no
          significant reduction in immunoreactivity was observed on
          incubating the <NUMEX TYPE="ORDINAL">first</NUMEX> antiserum with an excess of <ENAMEX TYPE="PRODUCT">SP</ENAMEX>,
          <ENAMEX TYPE="ORGANIZATION">eledoisin</ENAMEX> or kassinin. Thus, the <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> used, in the
          present work, principally recognizes NKA but shows some
          <ENAMEX TYPE="ORGANIZATION">cross</ENAMEX>-reactivity with <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX>. For this reason, the term "
          neurokinin-like immunoreactive " (NK-ir) is used to
          described the staining results in our <ENAMEX TYPE="SUBSTANCE">material</ENAMEX>. However,
          we have to indicate that the immunoreactivity found in
          this study is mainly due to <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX> (see and compare Figs.
          6B; <TIMEX TYPE="DATE">10A</TIMEX>; 11A,11<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>), since the distribution of <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX> is much
          less widespread in the human <ENAMEX TYPE="SUBSTANCE">brainstem</ENAMEX>, in comparison
          with the distribution found for <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX>(personal observation
          obtained after using a very specific rabbit anti-NKB
          <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> from <ENAMEX TYPE="GPE">Peninsula</ENAMEX>). Thus, the anti-NKB antibody
          (<ENAMEX TYPE="CONTACT_INFO">IHC 7357</ENAMEX>) showed the following crossreactivities: <NUMEX TYPE="PERCENT">100%</NUMEX>
          for <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX>, <NUMEX TYPE="PERCENT">2%</NUMEX> for physalaemin, <NUMEX TYPE="PERCENT">1%</NUMEX> for eledoisin, <NUMEX TYPE="PERCENT">0.6%</NUMEX> for
          kassinin, <NUMEX TYPE="PERCENT">0.2%</NUMEX> for substance P, <NUMEX TYPE="PERCENT">0.1%</NUMEX> for <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX> and <NUMEX TYPE="PERCENT">0%</NUMEX> for
          <ENAMEX TYPE="PERSON">neuropeptide K. Moreover</ENAMEX>, in the nuclei of the human
          <ENAMEX TYPE="ORGANIZATION">brainstem</ENAMEX> in which <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX> was observed, the density of the
          immunoreactivity for <ENAMEX TYPE="ORGANIZATION">NKB</ENAMEX> was lesser than that found in
          the same nuclei for <ENAMEX TYPE="ORGANIZATION">NKA</ENAMEX> (see and compare <ENAMEX TYPE="ORGANIZATION">Figs.</ENAMEX> <ENAMEX TYPE="PRODUCT">6B</ENAMEX>; <TIMEX TYPE="DATE">10A</TIMEX>;
          11A,11<ENAMEX TYPE="ORGANIZATION">B</ENAMEX>).
        
        
          Mapping
          <ENAMEX TYPE="PERSON">Mapping</ENAMEX> was carried out according to the atlas of the
          human brain of <ENAMEX TYPE="PERSON">Haines</ENAMEX> [ <TIMEX TYPE="DATE">36</TIMEX> ] , and the same atlas was
          used for the terminology of the brainstem nuclei. In
          addition, the atlas of <ENAMEX TYPE="ORGANIZATION">Paxinos et al.</ENAMEX> [ <TIMEX TYPE="DATE">37</TIMEX> ] was
          consulted.
          The number of immunostained cell <ENAMEX TYPE="PER_DESC">bodies</ENAMEX> appearing in
          each <ENAMEX TYPE="ORG_DESC">section</ENAMEX> from each <ENAMEX TYPE="PER_DESC">person</ENAMEX> was counted; a high density
          of <ENAMEX TYPE="ORGANIZATION">NK</ENAMEX>-ir perikarya was considered when we found more than
          20 cell <ENAMEX TYPE="PER_DESC">bodies</ENAMEX>/section; a moderate density when we found
          <NUMEX TYPE="CARDINAL">10-20</NUMEX> cell <ENAMEX TYPE="PER_DESC">bodies</ENAMEX>/section, and a low density when we
          found <NUMEX TYPE="CARDINAL">fewer than 10</NUMEX> cell <ENAMEX TYPE="PER_DESC">bodies</ENAMEX>/section. The density of
          the immunopositive <ENAMEX TYPE="SUBSTANCE">fibers</ENAMEX> was graded under microscopic
          observation into <NUMEX TYPE="CARDINAL">four</NUMEX> categories: high, moderate, low and
          single. This was accomplished by viewing the sections
          under bright-field illumination at a constant
          magnification with reference to photographs of defined
          series of <ENAMEX TYPE="SUBSTANCE">densities</ENAMEX> [ <TIMEX TYPE="DATE">38</TIMEX> ] .
          Finally, photomicrographs were obtained with a
          CoolSNAP digital camera attached to a <ENAMEX TYPE="NATIONALITY">Zeiss</ENAMEX> Axiophot
          microscope. To improve the visualization of the results,
          only the brightness and contrast of the images were
          adjusted without any further manipulation of the
          photographs.
        
      
      
        <ENAMEX TYPE="ORGANIZATION">Abbreviations</ENAMEX> used in figures
        
        - <NUMEX TYPE="CARDINAL">1</NUMEX> : Caudal end of the motor
        hypoglossal nucleus
        
        - <NUMEX TYPE="CARDINAL">2</NUMEX> : Caudal end of the dorsal motor
        nucleus of the vagus
        
        - <NUMEX TYPE="CARDINAL">4</NUMEX> : <ENAMEX TYPE="LOCATION">Area</ENAMEX> postrema
        
        - AbdNr : Abducens nerve
        
        - AbdNu : Abducens nucleus
        
        - AccNu : The nucleus of the accessory
        nerve
        
        - ACSp : <ENAMEX TYPE="ORGANIZATION">Anterior</ENAMEX> corticospinal
        tract
        
        - ALS : Anterolateral system
        
        - AMV : <ENAMEX TYPE="ORGANIZATION">Anterior</ENAMEX> medullary velum
        
        - ArNu : Arcuate nucleus
        
        - CA : Cerebral <ENAMEX TYPE="FAC_DESC">aqueduct</ENAMEX>
        
        <ENAMEX TYPE="PRODUCT">- CC</ENAMEX> : Crus cerebri
        
        - CeGy : Medullary or tegmental central
        <ENAMEX TYPE="EVENT">gray</ENAMEX>
        
        - CoBul : Corticobulbar fibers
        
        - CortNig : Corticonigral fibers
        
        - CSNu : Principal trigeminal
        nucleus
        
        - CSp : Corticospinal fibers
        
        - CTT : <ENAMEX TYPE="ORGANIZATION">Central</ENAMEX> tegmental tract
        
        - <ENAMEX TYPE="NATIONALITY">D</ENAMEX> : Dorsal
        
        - DAO : Dorsal accessory olivary
        nucleus
        
        - DtegDec : Dorsal tegmental
        decussation
        
        - DLF : Dorsal part of the medial
        longitudinal fascicle
        
        - DMNu : <ENAMEX TYPE="GPE">Dorsal</ENAMEX> motor nucleus of the
        vagus
        
        - DSCT : Dorsal spinocerebellar
        tract
        
        - DTTr : Dorsal trigeminothalamic
        tract
        
        - EAF : <ENAMEX TYPE="ORGANIZATION">External</ENAMEX> arcuate fibers
        
        - <ENAMEX TYPE="GPE">Fac</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">G</ENAMEX> : Facial nerve, internal
        genu
        
        - FacNr : Facial nerve
        
        - FacNu : <ENAMEX TYPE="ORGANIZATION">Motor</ENAMEX> facial nucleus
        
        - Fcu : Fasciculus cuneatus
        
        - FGr : Fasciculus gracilis
        
        - Fpon : Frontopontine fibers
        
        - g : Gelatinosa
        
        - HyNu : <ENAMEX TYPE="ORGANIZATION">Motor</ENAMEX> hypoglossal nucleus
        
        - IAF : <ENAMEX TYPE="ORGANIZATION">Internal</ENAMEX> arcuate fibers
        
        - <ENAMEX TYPE="ORGANIZATION">IC</ENAMEX>, <ENAMEX TYPE="WORK_OF_ART">Br : Inferior colliculus</ENAMEX>,
        brachium
        
        - <ENAMEX TYPE="ORGANIZATION">IC</ENAMEX>, CNu : <ENAMEX TYPE="PERSON">Inferior</ENAMEX> colliculus,
        central nucleus
        
        <ENAMEX TYPE="CONTACT_INFO">- IC, Com : Inferior colliculus,</ENAMEX>
        commissure
        
        - <ENAMEX TYPE="ORGANIZATION">IC</ENAMEX>, LZ : <ENAMEX TYPE="PERSON">Inferior</ENAMEX> colliculus, <ENAMEX TYPE="DISEASE">lateral</ENAMEX>
        zone
        
        - ICP : <ENAMEX TYPE="PERSON">Inferior</ENAMEX> cerebellar
        peduncle
        
        - IPFo : Interpeduncular fossa
        
        - IPNu : Interpeduncular nucleus
        
        - JRB : Juxtarestiform body
        
        - LCNu : <ENAMEX TYPE="DISEASE">Lateral cuneate</ENAMEX> nucleus
        
        - LL : <ENAMEX TYPE="DISEASE">Lateral</ENAMEX> lemniscus
        
        - <ENAMEX TYPE="ORGANIZATION">LL</ENAMEX>, <ENAMEX TYPE="WORK_OF_ART">Nu : Nuclei of the lateral</ENAMEX>
        <ENAMEX TYPE="ORGANIZATION">lemniscus</ENAMEX> (dorsal, ventral)
        
        - LoCer : Locus ceruleus
        
        - LRNu : <ENAMEX TYPE="DISEASE">Lateral reticular</ENAMEX> nucleus
        
        - <ENAMEX TYPE="ORGANIZATION">M</ENAMEX> : Medial
        
        - m : Magnocellular
        
        - MAO : Medial accessory olivary
        nucleus
        
        - MCP : <ENAMEX TYPE="ORGANIZATION">Middle</ENAMEX> cerebellar peduncle
        
        - MesNu : Mesencephalic trigeminal
        nucleus
        
        - MGB : Medial geniculate body
        
        - MesTr : <ENAMEX TYPE="ORGANIZATION">Mesencephalic</ENAMEX> tract of the
        trigeminal nerve
        
        - ML : Medial lemniscus
        
        - MLF : Medial longitudinal
        fascicle
        
        - MVN : Medial vestibular nucleus
        
        - NigSt : Nigrostriatal fibers
        
        - NuAm : <ENAMEX TYPE="PERSON">Nucleus</ENAMEX> ambiguus
        
        - NuCu : Cuneate nucleus
        
        - NuGr : Gracile nucleus
        
        - NuPp : <ENAMEX TYPE="PERSON">Nucleus</ENAMEX> prepositus
        hypoglossi
        
        - OcbF : Olivocerebellar fibers
        
        - OcNr : Oculomotor nerve
        
        - OcNu : Oculomotor nucleus
        
        - Opon : Occipitopontine fibers
        
        - PAG : Periaqueductal gray
        
        - PalNig : Pallidonigral fibers
        
        - PCbF : Pontocerebellar fibers
        
        <ENAMEX TYPE="ORGANIZATION">- PO</ENAMEX> : Principal part of the inferior
        olivary nucleus
        
        - PonNu : Pontine nuclei
        
        - Ppon : Parietopontine fibers
        
        - Py : <ENAMEX TYPE="ORGANIZATION">Pyramidal</ENAMEX> tract
        
        - RB : Restiform body
        
        - RetF : Reticular formation
        
        - RetSp : <ENAMEX TYPE="ORGANIZATION">Reticulospinal</ENAMEX> tract
        
        - RNu : <ENAMEX TYPE="ORGANIZATION">Red</ENAMEX> nucleus
        
        - RuSp : <ENAMEX TYPE="ORGANIZATION">Rubrospinal</ENAMEX> tract
        
        - SC : <ENAMEX TYPE="ORGANIZATION">Superior</ENAMEX> colliculus
        
        - SCP : <ENAMEX TYPE="ORGANIZATION">Superior</ENAMEX> cerebellar
        peduncle
        
        - <ENAMEX TYPE="ORGANIZATION">SCP</ENAMEX>, <TIMEX TYPE="DATE">Dec</TIMEX> : <ENAMEX TYPE="ORGANIZATION">Superior</ENAMEX> cerebellar
        peduncle, decussation
        
        - SN : Substantia nigra
        
        - SO : <ENAMEX TYPE="ORGANIZATION">Superior</ENAMEX> olive
        
        - SolNu : <ENAMEX TYPE="PERSON">Nucleus</ENAMEX> of the solitary
        tract
        
        - SolTr : <ENAMEX TYPE="ORGANIZATION">Solitary</ENAMEX> tract
        
        - SpTec : <ENAMEX TYPE="ORGANIZATION">Spinotectal</ENAMEX> tract
        
        - SpTh : <ENAMEX TYPE="ORGANIZATION">Spinothalamic</ENAMEX> tract
        
        - SpTNu : <ENAMEX TYPE="PERSON">Spinal</ENAMEX> trigeminal nucleus
        
        - SpTT : <ENAMEX TYPE="ANIMAL">Spinal trigeminal</ENAMEX> tract
        
        - SpVN : <ENAMEX TYPE="PERSON">Spinal</ENAMEX> (inferior) vestibular
        nucleus
        
        - SSNu : <ENAMEX TYPE="ORGANIZATION">Superior</ENAMEX> salivatory
        nucleus
        
        - SVN : <ENAMEX TYPE="ORGANIZATION">Superior</ENAMEX> vestibular nucleus
        
        - TecSP : <ENAMEX TYPE="ORGANIZATION">Tectospinal</ENAMEX> tract
        
        - Tpon : Temporopontine fibers
        
        - TrapB : Trapezoid body
        
        - TrapNu : Trapezoid nucleus
        
        - TriMoNu : <ENAMEX TYPE="GPE">Trigeminal</ENAMEX> motor nucleus
        (caudal part)
        
        - TriNr : Trigeminal nerve
        
        - TroNr : Trochlear nerve
        
        - V : Ventricle
        
        - VesSp : <ENAMEX TYPE="ORGANIZATION">Vestibulospinal</ENAMEX> tract
        
        - VSCT : Ventral spinocerebellar
        tract
        
        - VTegDec : Ventral tegmental
        decussations
        
        - VTTr : Ventral trigeminothalamic
        tract
      
      
        <ENAMEX TYPE="PER_DESC">Authors</ENAMEX>' contribution
        <ENAMEX TYPE="ORGANIZATION">RC</ENAMEX> carried out the cartography, conceived the study and
        participated in its design and coordination. FM and <ENAMEX TYPE="PRODUCT">MB</ENAMEX>
        carried out the immunocytochemical technique and the
        <ENAMEX TYPE="ORGANIZATION">cartography</ENAMEX>. <ENAMEX TYPE="PRODUCT">VS</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">PS</ENAMEX> and <ENAMEX TYPE="WORK_OF_ART">ER</ENAMEX> initials carried out the
        <ENAMEX TYPE="ORGANIZATION">autopsies</ENAMEX> and the perfusion of the brains, as well as they
        obtained the brain sections. <ENAMEX TYPE="ORGANIZATION">ZDC</ENAMEX>, <ENAMEX TYPE="PERSON">JAN</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">PM</ENAMEX> initials
        carried out the immunocytochemical technique, the
        <ENAMEX TYPE="ORGANIZATION">cartography</ENAMEX> and drafted the manuscript. <ENAMEX TYPE="ORGANIZATION">GT</ENAMEX> obtained the
        <NUMEX TYPE="ORDINAL">first</NUMEX> <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> used in this study. SGB initials drafted the
        <ENAMEX TYPE="PERSON">manuscript</ENAMEX>.
      
    
  
